ACE Inhibitors Beat ARBs for Cardiovascular Mortality in High-Risk Patients

This placebo-controlled meta-analysis gives anticoagulation and cardiology pharmacists a cleaner evidence base for preferring ACE inhibitors over ARBs as first-line renin-angiotensin blockade in high-risk patients without heart failure.

📅 Journal publication: Jul 2026 (online Jul 28, 2026) · Last updated: Jul 30, 2026

ACE inhibitorsangiotensin receptor blockersARBsperindoprilramipriltelmisartanRAAS inhibitorscardiovascular mortalitysecondary preventionmeta-analysishypertensioncoronary artery disease Cardiology

Background Information

ACE inhibitors outperform ARBs in reducing heart risks.

This study evaluates the differential impact of angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) on cardiovascular outcomes in at-risk patients without heart failure. ACE-Is reduced cardiovascular mortality by 12% and myocardial infarction by 17% compared to placebo, while ARBs did not show similar benefits. ACE-Is demonstrated superior cardiovascular protection compared to ARBs in patients at high cardiovascular risk, suggesting a preferential use of ACE-Is for these patients. ACE inhibitors offer greater cardiovascular protection than ARBs in high-risk patients without heart failure.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.

Subscribe for $8/month → Read this one free →

Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Masi S, Savarese G, Orsini N, Strauss MH

Citation: Masi S, Savarese G, Orsini N, et al. Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular and non-cardiovascular outcomes in patients at high/very-high cardiovascular risk without heart failure: a systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials (†). European heart journal open. 2026;6(4):oeag119. doi:10.1093/ehjopen/oeag119

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Founding member rate

$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →

Free account, no credit card. Includes 1 full deep analysis every month.

Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.